Numerous studies have demonstrated that LIQ can modulate the inflammatory response associated with various chronic conditions, including non-alcoholic fatty liver disease (NAFLD), arthritis, asthma, hepatic sinusoidal obstruction syndrome (HSOS), etc. For example, Bao et al. revealed that LIQ treatment in high-fat diet-induced NAFLD mice resulted in improved lipid metabolism, reduced insulin resistance, and decreased inflammatory markers, potentially mediated through the activation of PI3K/Akt signaling pathway [65]. The gene discussed is AKT1; the disease is metabolic dysfunction-associated steatotic liver disease.